Human Genome Sciences, Inc.

J. Craig Venter Institute

Other

Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

Glaxosmithkline Biologicals Sa

Smithkline Beecham Corporation

Intercell Ag

Valneva Austria Gmbh

Novartis Vaccines and Diagnostics Srl

Claire M Fraser

Maria Scarselli

Guido Grandi

Mark D Adams

Vega Masignani

Herve Tettelin

Ewen F Kirkness

Rino Rappuoli

Mariagrazia Pizza

Gregg A Hastings

Lisa M Fitzgerald

Norman H Lee

Judith A Blake

Fred H Drake

Maxine Gowan

Craig A Rosen

Cesira Galeotti

John Telford

Vincenzo Scarlato

Erin Hickey

J Craig Venter

Giulio Ratti

Marirosa Mora

Jeremy Petersen

Ying-Fei Wei

William A Haseltine

Robert D Fleischmann

Rebecca A Fuldner

Andreas Meinke

Eszter Nagy

Jeannine D Gocayne

Wolfgang Zauner

Christoph Klade

Oresta Vytvytska

Duc Bui Minh

Hildegard Etz

Agnieszka Dryla

Martin Hafner

Steven Gill

Thomas Weichhart

Uwe Von Ahsen

Tamas Henics

Steven M Ruben

Brigitte Tempelmaier

Guo-Liang Yu

Steve Ruben

Davide Serruto

Hervé Tettelin

Bert Vogelstein

Kenneth W Kinzler

Nicholas C Nicolaides

Nickolas Papadopoulos

Hamilton O Smith

Christine Marie Debouck

Owen White

Julie A Rood

Clyde A Hutchison, Iii

Craig Venter

Mariarosa Mora

A Scott Durkin

Steven L Salzberg

Gu-Liang Yu

Maxine Gowen

Brigitre Tempelmaier

Maria Rosa Mora

Giulo Ratti

Jeremy D Peterson

Craig Ventor

Nils Kåre Birkeland

Ingvar Eidhammer

Inge Jonassen

Harald B Jensen

Torleiv Lien

Johan R Lillehaug

Ivar Lossius

Jonathan A Eisen

Duc Minh Bui

Mariagratia Pizza

Enzo Scalato

The invention provides proteins from group B() and group A(), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

Nucleic acids and proteins from streptococcus groups A and B

[object Object]

The invention provides proteins from, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

Method for identification, isolation and production of antigens to a specific pathogen

Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis.

The invention provides proteins from group B streptococcus () and group A streptococcus (), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

Nucleic acids and proteins fromgroups A and B

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:&#x2014;providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,&#x2014;providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,&#x2014;screening said at least one expression library with said antibody preparation,&#x2014;identifying antigens which bind in said screening to antibodies in said antibody preparation,&#x2014;screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,&#x2014;identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and&#x2014;optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

Growing community of inventors

Gueenstown, MD, United States of America

Claire M Fraser